Ayman Madi

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

Tim Maughan, Richard Adams, Christopher G. Smith et al. · The Lancet · 2011 · 964 citations

Gastrointestinal Oncology, Medicine, Randomised Phase 3 +8

Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial

Charles S. Fuchs, Kohei Shitara, Maria Di Bartolomeo et al. · The Lancet Oncology · 2019 · 276 citations · Full text

First-line Therapy, Gastrointestinal Oncology, Medicine +6

Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

Richard Adams, Angela Meade, Richard H. Wilson et al. · The Lancet Oncology · 2011 · 262 citations · Full text

Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial

Harpreet Wasan, Angela Meade, Richard Adams et al. · The Lancet Oncology · 2014 · 118 citations · Full text

Identification of potentially responsive subsets when cetuximab is added to oxaliplatin-fluoropyrimidine chemotherapy (CT) in first-line advanced colorectal cancer (aCRC): Mature results of the MRC COIN trial.

Tim Maughan, Richard Adams, Christopher G. Smith et al. · Journal of Clinical Oncology · 2010 · 49 citations

Cancer Management, Responsive Subsets, Pharmacotherapy +16